These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 23346156)
1. Decreased Metabolism in the Cerebral Cortex in Early-Stage Huntington's Disease: A Possible Biomarker of Disease Progression? Shin H; Kim MH; Lee SJ; Lee KH; Kim MJ; Kim JS; Cho JW J Clin Neurol; 2013 Jan; 9(1):21-5. PubMed ID: 23346156 [TBL] [Abstract][Full Text] [Related]
2. Striatal hypometabolism in premanifest and manifest Huntington's disease patients. López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245 [TBL] [Abstract][Full Text] [Related]
3. Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis. Fusilli C; Migliore S; Mazza T; Consoli F; De Luca A; Barbagallo G; Ciammola A; Gatto EM; Cesarini M; Etcheverry JL; Parisi V; Al-Oraimi M; Al-Harrasi S; Al-Salmi Q; Marano M; Vonsattel JG; Sabatini U; Landwehrmeyer GB; Squitieri F Lancet Neurol; 2018 Nov; 17(11):986-993. PubMed ID: 30243861 [TBL] [Abstract][Full Text] [Related]
4. [Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea]. Vojvodić N; Culjković B; Romac S; Stojković O; Sternić N; Sokić D; Kostić VS Srp Arh Celok Lek; 1998; 126(3-4):77-82. PubMed ID: 9863360 [TBL] [Abstract][Full Text] [Related]
5. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012 [TBL] [Abstract][Full Text] [Related]
6. PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression. Fazio P; Fitzer-Attas CJ; Mrzljak L; Bronzova J; Nag S; Warner JH; Landwehrmeyer B; Al-Tawil N; Halldin C; Forsberg A; Ware J; Dilda V; Wood A; Sampaio C; Varrone A; Mov Disord; 2020 Apr; 35(4):606-615. PubMed ID: 31967355 [TBL] [Abstract][Full Text] [Related]
7. Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease. Sampedro F; Martínez-Horta S; Perez-Perez J; Horta-Barba A; Lopez-Mora DA; Camacho V; Fernández-León A; Gomez-Anson B; Carrió I; Kulisevsky J Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1111-1116. PubMed ID: 30627816 [TBL] [Abstract][Full Text] [Related]
9. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. Feigin A; Leenders KL; Moeller JR; Missimer J; Kuenig G; Spetsieris P; Antonini A; Eidelberg D J Nucl Med; 2001 Nov; 42(11):1591-5. PubMed ID: 11696626 [TBL] [Abstract][Full Text] [Related]
10. Expression of the Huntington's disease (IT15) protein product in HD patients. Schilling G; Sharp AH; Loev SJ; Wagster MV; Li SH; Stine OC; Ross CA Hum Mol Genet; 1995 Aug; 4(8):1365-71. PubMed ID: 7581375 [TBL] [Abstract][Full Text] [Related]
11. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study. Paulsen JS; Long JD; Ross CA; Harrington DL; Erwin CJ; Williams JK; Westervelt HJ; Johnson HJ; Aylward EH; Zhang Y; Bockholt HJ; Barker RA; Lancet Neurol; 2014 Dec; 13(12):1193-201. PubMed ID: 25453459 [TBL] [Abstract][Full Text] [Related]
13. A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study. Rosas HD; Reuter M; Doros G; Lee SY; Triggs T; Malarick K; Fischl B; Salat DH; Hersch SM Mov Disord; 2011 Aug; 26(9):1691-7. PubMed ID: 21611979 [TBL] [Abstract][Full Text] [Related]